http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 07:45:30 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+to+present+21+abstracts+at+SLEEP+2026+conference/26602513.html <p>Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced it will present 21 abstracts at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies, taking place June 14-17, 2026, in Baltimore. The presentations include 11 late-breaking abstracts focused on Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for treating narcolepsy and idiopathic hypersomnia.</p><p>The research presentations will cover post-hoc analyses of the DUET study examining sleep inertia in narcolepsy patients, treatment outcomes for idiopathic hypersomnia participants, and dosing patterns above the standard 9 grams per night recommendation for narcolepsy patients. Six presentations will feature findings from the LYRICAL study examining real-world http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+to+present+21+abstracts+at+SLEEP+2026+conference/26602513.html Thu, 04 Jun 2026 07:45:30 -0400 JAZZ http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html <div class="xn-content"> <p class="prntac"><i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia</i></p><p><i>For <location value="LC/us" idsrc="xmltag.org" >U.S</location>. media and investors only</i></p><p><span class="legendSpanClass"><location value="LU/us.md.dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span> plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40^th annual meeting of the Associated Professional Sleep Societies (APSS), taking place <chron>June 14-17, 2026</chron>, in <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore</location>. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+to+Present+Comprehensive+Data+at+SLEEP+2026+Highlighting+Broad+Treatment+Effects+of+Xywav%C2%AE+%28calcium%2C+magnesium%2C+potassium%2C+and+sodium+oxybates%29+Oral+Solution+for+People+with+Narc/26602511.html Thu, 04 Jun 2026 07:45:00 -0400 A.22403962 A.42688798 JAZZ O.00657036 O.00861113 O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Jun+01++Filed+by%3A+COZADD+BRUCE+C/26600206.html si-local-file:///var/storage/secattach/20260603/26600206.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Jun+01++Filed+by%3A+COZADD+BRUCE+C/26600206.html Wed, 03 Jun 2026 17:10:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Jun+01++Filed+by%3A+COZADD+BRUCE+C/26600206.html si-local-file:///var/storage/secattach/20260603/26600206.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+Jun+01++Filed+by%3A+COZADD+BRUCE+C/26600206.html Wed, 03 Jun 2026 17:10:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+COZADD+BRUCE+C/26583755.html si-local-file:///var/storage/secattach/20260601/26583755.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+COZADD+BRUCE+C/26583755.html Mon, 01 Jun 2026 16:13:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+COZADD+BRUCE+C/26583755.html si-local-file:///var/storage/secattach/20260601/26583755.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+COZADD+BRUCE+C/26583755.html Mon, 01 Jun 2026 16:13:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Patil+Neena+M/26583648.html si-local-file:///var/storage/secattach/20260601/26583648.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Patil+Neena+M/26583648.html Mon, 01 Jun 2026 16:10:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Patil+Neena+M/26583648.html si-local-file:///var/storage/secattach/20260601/26583648.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Patil+Neena+M/26583648.html Mon, 01 Jun 2026 16:10:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Pearce+Samantha/26583575.html si-local-file:///var/storage/secattach/20260601/26583575.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Pearce+Samantha/26583575.html Mon, 01 Jun 2026 16:08:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Pearce+Samantha/26583575.html si-local-file:///var/storage/secattach/20260601/26583575.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Pearce+Samantha/26583575.html Mon, 01 Jun 2026 16:08:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Mulligan+Seamus/26583346.html si-local-file:///var/storage/secattach/20260601/26583346.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Mulligan+Seamus/26583346.html Mon, 01 Jun 2026 16:03:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Mulligan+Seamus/26583346.html si-local-file:///var/storage/secattach/20260601/26583346.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Jazz+Pharmaceuticals++++++For%3A+May+28++Filed+by%3A+Mulligan+Seamus/26583346.html Mon, 01 Jun 2026 16:03:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Jazz+Pharmaceuticals++++++For%3A+Jul+23/26575247.html si-local-file:///var/storage/secattach/20260529/26575247.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Jazz+Pharmaceuticals++++++For%3A+Jul+23/26575247.html Fri, 29 May 2026 16:12:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Jazz+Pharmaceuticals++++++For%3A+Jul+23/26575247.html si-local-file:///var/storage/secattach/20260529/26575247.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Jazz+Pharmaceuticals++++++For%3A+Jul+23/26575247.html Fri, 29 May 2026 16:12:00 -0400 JAZZ O.12498162